Venetoclax Plus Rituximab Receives Breakthrough Therapy Designation for CLLJason HoffmanPharmD
Pirtobrutinib and BTK Inhibitors in the CLL Treatment Landscape April Is Stress Awareness Month: A Little Humbling Self-Awareness May Go a Long Way Empowering Oncology Pharmacists: Driving Innovation and Advancement Through Pharmacist-Led Research Balancing Health Tech Innovation With Safety: Navigating ...
Bladder Cancer Breakthrough: Understanding Cretostimogene Cretostimogene Effective for BCG-Unresponsive Bladder Cancer: Phase 3 Data Kamran on the Shift Towards Early Salvage Radiation After Prostatectomy Enhanced NMIBC Progression Risk Prediction With a Novel AI Model ...
Liso-cel consists of a defined CD4 and CD8 composition and 4-1BB costimulatory domain; its defined composition allows administration of a precise dose of treatment. The CAR T-cell therapy was granted a breakthrough therapy designation by the FDA for patients with diffuse large B-cell lymphoma, ...
Strategies for Neoadjuvant NSCLC Treatment Nichole Tucker;Benny Weskler, MBA, MD, FACS, FACCP September 2nd 2023 Podcast In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer. ...
Bladder Cancer Breakthrough: Understanding Cretostimogene Cretostimogene Effective for BCG-Unresponsive Bladder Cancer: Phase 3 Data Kamran on the Shift Towards Early Salvage Radiation After Prostatectomy Enhanced NMIBC Progression Risk Prediction With a Novel AI Model ...
In an interview, Ira Zackon, MD, emphasized the need for community-based, inclusive care, and the importance of utilizing technology to address disparities in the modern era of chronic lymphocytic leukemia treatment. Ira Zackon, MD Recent findings suggest an association between race and socio...
William G. Wierda, MD, PhD, discusses the take home message from the phase III MURANO trial that identified venetoclax plus rituximab as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia.
But the [adverse] effect profile matters a lot to patients because people want to have these drugs for months, if not years, so that was 1 temporal trend we observed from 2020 through 2023. 0:41 | The second thing we observed is that there really was not a big impact of the social ...
Bladder Cancer Breakthrough: Understanding CretostimogeneRelated Content Chronic Lymphocytic Leukemia |Interviews CBT Benefits Cancer Patients' Mental Health & Treatment Adherence Sabrina Serani May 3rd 2025 Article Sofia Chernoff, PsyD, MSEd, discussed how cognitive behavioral therapy helps cancer patients...